Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma

Cancer

Volumn 116, Issue 1, 2010, Pages 203-209

  McWilliams, Robert R ^a   Petersen, Gloria M ^a   Rabe, Kari G ^a   Holtegaard, Leonard M ^a   Lynch, Pamela J ^a   Bishop, Michele D ^b   Highsmith Jr , W Edward ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cystic fibrosis transmembrane conductance regulator; Disease associated mutation; Molecular epidemiology; Pancreatic neoplasms

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISTANT METASTASIS; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC RISK; GENOTYPE; GROUPS BY AGE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PANCREATITIS; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; RISK; SMOKING;

EID: 74549164128     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24697     Document Type: Article

References (40)

1. Riela A, Zinsmeister AR, Melton LJ III, et al. Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988. Mayo Clin Proc. 1992;67:839-845.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
3. Petersen GM, Hruban RH. Familial pancreatic cancer: where are we in 2003? J Natl Cancer Inst. 2003;95:180-181.
4. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med. 1998;339:645-652.
5. Durno C, Corey M, Zielenski J, et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology. 2002;123:1857-1864.
6. Lowenfels AB, Maisonneuve P, Cavallini G, et al. International Pancreatitis Study Group. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1433-1437.
7. Tsongalis GJ, Faber G, Dalldorf FG, et al. Association of pancreatic adenocarcinoma, mild lung disease, and ΔF508 mutation in a cystic fibrosis patient. Clin Chem. 1994;40:1972-1974.
8. Davis TM, Sawicka EH. Adenocarcinoma in cystic fibrosis. Thorax. 1985;40:199-200.
9. McIntosh JC, Schoumacher RA, Tiller RE. Pancreatic adenocarcinoma in a patient with cystic fibrosis. Am J Med. 1988;85:592.
10. Surveillance, Epidemiology, and End Results Program. SEER*Stat Database. Available at: http://www.seer.cancer.-gov. Accessed on January 13, 2009.
11. Sheldon CD, Hodson ME, Carpenter LM, et al. A cohort study of cystic fibrosis and malignancy. Br J Cancer. 1993;68:1025-1028.
12. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. Cystic Fibrosis and Cancer Study Group. The risk of cancer among patients with cystic fibrosis. N Engl J Med. 1995;332:494-499.
13. McWilliams RR, Highsmith WE, Rabe KG, et al. Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. Gut. 2005;54:1661-1662.
14. Wang L, Bamlet WR, de Andrade M, et al. Mitochondrial genetic polymorphisms and pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:1455-1459.
15. Amos JA, Bridge-Cook P, Ponek V, et al. A universal array-based multiplexed test for cystic fibrosis carrier screening. Expert Rev Mol Diagn. 2006;6:15-22.
16. Farrell PM, Rosenstein BJ, White TB, et al. Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153:S4-S14.
17. Strom CM, Janeszco R, Quan F, et al. Technical validation of a TM Biosciences Luminex-based multiplex assay for detecting the American College of Medical Genetics recommended cystic fibrosis mutation panel. J Mol Diagn. 2006;8:371-375.
18. Johnson MA, Yoshitomi MJ, Richards CS. A comparative study of 5 technologically diverse CFTR testing platforms. J Mol Diagn. 2007;9:401-407.
19. Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet. 1992;50:222-228.
20. Malats N, Casals T, Porta M, et al. Cystic fibrosis transmembrane regulator (CFTR) ΔF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. Gut. 2001;48:70-74.
21. Matsubayashi H, Fukushima N, Sato N, et al. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol Ther. 2003;2:652-655.
22. Bobadilla JL, Macek M Jr, Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations: correlation with incidence data and application to screening. Hum Mutat. 2002;19:575-606.
23. Layer P, DiMagno EP. Early and late onset in idiopathic and alcoholic chronic pancreatitis: different clinical courses. Surg Clin North Am. 1999;79:847-860.
24. Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Risk factors for cancer in hereditary pancreatitis. Med Clin North Am. 2000;84:565-573.
25. Ferec C, Novelli G, Verlingue C, et al. Identification of 6 novel CFTR mutations in a sample of Italian cystic fibrosis patients. Mol Cell Probes. 1995;9:135-137.
26. Cuppens H, Jaspers M, Lin W, et al. Exon 10 skipping resulting from the E528E polymorphism [abstract]. Pediatr Pulmonol. 1998;26:302.
27. Clain J, Lehmann-Che J, Girodon E, et al. A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype. Hum Genet. 2005;116:454-460.
28. Padoan R, Genoni S, Moretti E, et al. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis. Acta Paediatr. 2002;91:82-87.
29. Boyne J, Evans S, Pollitt RJ, et al. Many DF508 heterozygote neonates with transient hypertrypsinaemia have a second, mild CFTR mutation. J Med Genet. 2000;37:543-547.
30. Monaghan KG, Highsmith WE, Amos J, et al. Genotypephenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genet Med. 2004;6:421-425.
31. Wei L, Vankeerberghen A, Jaspers M, et al. Suppressive interactions between mutations located in the 2 nucleotide binding domains of CFTR. FEBS Lett. 2000;473:149-153.
32. Chu CS, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet. 1993;3:151-156.
33. Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332:1475-1480.
34. Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet. 2005;118:372-381.
35. Weiss FU, Simon P, Bogdanova N, et al. Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls. Gut. 2005;54:1456-1460.
36. Gasparini P, Arbustini E, Restagno G, et al. Analysis of 31 CFTR mutations by polymerase chain reaction/oligonucleotide ligation assay in a pilot screening of 4476 newborns for cystic fibrosis. J Med Screen. 1999;6:67-69.
37. Konialis CP, Hagnefelt B, Kazamia C, et al. CFTR ΔF508 mutation detection from dried blood samples in the first trimester of pregnancy: a possible routine prenatal screening strategy for cystic fibrosis? Fetal Diagn Ther. 2007;22:41-44.
38. Fries MH, Bashford M, Nunes M. Implementing prenatal screening for cystic fibrosis in routine obstetric practice. Am J Obstet Gynecol. 2005;192:527-534.
39. Choi JY, Muallem D, Kiselyov K, et al. Aberrant CFTR-dependent HCO3 transport in mutations associated with cystic fibrosis. Nature. 2001;410:94-97.
40. Ahmed N, Corey M, Forstner G, et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut. 2003;52:1159-1164.